SCTX

Scribe Therapeutics Inc.
CAPPED RATING

Scribe Therapeutics Inc. (SCTX) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Profitability (D-). The rating has held at C- for 3 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
B-
Factor Score 2.9 / 5.0
Growth
D
Factor Score 1.4 / 5.0
Profitability
D-
Factor Score 0.8 / 5.0
Momentum
C+
Factor Score 2.8 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -4.9
EV / EBITDA N/A
Rev Growth YoY -91.9%
Gross Margin 0.0%
Price Return 3M -22.8%
Price Return 12M -13.8%
Catalyst Signal 0.00
Market Cap $309.7M
TTM Revenue $14.8M
Price / Sales 20.9
ROE N/A

Historical Factor Score Progression

Held C- for 3 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 B- (2.9) D (1.4) D- (0.8) C+ (2.8) C+ (2.6) C- (2.1)
2026-11-07 B- (3.0) D (1.5) F (0.5) C (2.3) C+ (2.7) C- (2.0)
2026-10-31 B- (3.0) D (1.4) F (0.6) C (2.2) C+ (2.7) C- (2.0)
2026-10-24 B- (3.0) D (1.4) F (0.5) C+ (2.7) C+ (2.6) C- (2.0)
2026-10-17 B- (3.0) D (1.4) F (0.5) A- (4.0) C+ (2.6) C (2.3)
Page 1 of 4